NO20053344D0 - Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser. - Google Patents

Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.

Info

Publication number
NO20053344D0
NO20053344D0 NO20053344A NO20053344A NO20053344D0 NO 20053344 D0 NO20053344 D0 NO 20053344D0 NO 20053344 A NO20053344 A NO 20053344A NO 20053344 A NO20053344 A NO 20053344A NO 20053344 D0 NO20053344 D0 NO 20053344D0
Authority
NO
Norway
Prior art keywords
genetically modified
generating
organism
modified organism
active substances
Prior art date
Application number
NO20053344A
Other languages
English (en)
Other versions
NO20053344L (no
Inventor
Almut Nitsche
Ekkehard Leberer
Bert Klebl
Anja Stadler
Rosemarie Sollner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20053344L publication Critical patent/NO20053344L/no
Publication of NO20053344D0 publication Critical patent/NO20053344D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033Rearing or breeding invertebrates; New breeds of invertebrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1072Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1079Screening libraries by altering the phenotype or phenotypic trait of the host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1086Preparation or screening of expression libraries, e.g. reporter assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Environmental Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20053344A 2002-12-17 2005-07-08 Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser. NO20053344D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10258885A DE10258885A1 (de) 2002-12-17 2002-12-17 Verfahren zur Generierung eines gentechnisch veränderten Organismus
PCT/EP2003/012870 WO2004055206A1 (de) 2002-12-17 2003-11-18 Verfahren zur generierung eines gentechnisch veränderten organismus für das wirk substanzscreening

Publications (2)

Publication Number Publication Date
NO20053344L NO20053344L (no) 2005-07-08
NO20053344D0 true NO20053344D0 (no) 2005-07-08

Family

ID=32519000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053344A NO20053344D0 (no) 2002-12-17 2005-07-08 Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.

Country Status (14)

Country Link
US (1) US20040143854A1 (no)
EP (1) EP1576186B1 (no)
JP (1) JP4630067B2 (no)
KR (2) KR20120038025A (no)
CN (1) CN1726290B (no)
AT (1) ATE508201T1 (no)
AU (1) AU2003283409A1 (no)
CA (1) CA2509333A1 (no)
DE (2) DE10258885A1 (no)
HK (1) HK1087734A1 (no)
NO (1) NO20053344D0 (no)
RU (1) RU2376364C2 (no)
WO (1) WO2004055206A1 (no)
ZA (1) ZA200504212B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2006014899A2 (en) * 2004-07-26 2006-02-09 Dow Global Technologies Inc. Process for improved protein expression by strain engineering
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
WO2007124115A2 (en) * 2006-04-20 2007-11-01 Trustees Of Boston College Compositions and methods for identifying inhibitors and activators of cyclic amp phosphodiesterases
WO2007143434A2 (en) * 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AU2008245696B2 (en) 2007-04-27 2013-11-07 Pelican Technology Holdings, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2632250A1 (en) * 2010-10-29 2013-09-04 F.Hoffmann-La Roche Ag Murine model of inflammation with il33 n-terminal domain deletion
HUP1100657A2 (en) * 2011-11-29 2013-06-28 Eotvos Lorand Tudomanyegyetem Transgenic caenorhabditis elegans
CN110172454B (zh) * 2019-05-23 2020-11-13 浙江大学 一种s-腺苷甲硫氨酸合成酶突变体及其高通量筛选方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188950C (en) * 1994-04-26 2001-07-03 James R. Broach Functional expression of mammalian adenylyl cyclase in yeast
CA2277414A1 (en) * 1997-11-07 1999-05-20 Georges Natsoulis Surrogate genetics target characterization method
AU2596800A (en) * 1998-12-31 2000-07-31 Iconix Pharmaceuticals, Inc. Method for generating a pathway reporter system
WO2001046403A1 (en) * 1999-12-22 2001-06-28 Iconix Pharmaceuticals, Inc. Synthetic lethal expression screen
CA2437383A1 (en) * 2001-02-02 2002-08-15 Raymond Kim Alteration of phenotype due to heterologous genes
US20030044866A1 (en) * 2001-08-15 2003-03-06 Charles Boone Yeast arrays, methods of making such arrays, and methods of analyzing such arrays

Also Published As

Publication number Publication date
AU2003283409A1 (en) 2004-07-09
KR101215854B1 (ko) 2012-12-31
HK1087734A1 (en) 2006-10-20
NO20053344L (no) 2005-07-08
WO2004055206A1 (de) 2004-07-01
JP2006509512A (ja) 2006-03-23
ATE508201T1 (de) 2011-05-15
ZA200504212B (en) 2006-02-22
US20040143854A1 (en) 2004-07-22
KR20050085806A (ko) 2005-08-29
EP1576186B1 (de) 2011-05-04
DE10258885A1 (de) 2004-07-15
KR20120038025A (ko) 2012-04-20
CA2509333A1 (en) 2004-07-01
DE50313671D1 (de) 2011-06-16
RU2005122470A (ru) 2006-05-10
JP4630067B2 (ja) 2011-02-09
RU2376364C2 (ru) 2009-12-20
CN1726290A (zh) 2006-01-25
EP1576186A1 (de) 2005-09-21
CN1726290B (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
NO20053344L (no) Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.
ATE269414T1 (de) Verfahren zur drogenuntersuchung
ATE357537T1 (de) Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren
DE60035196D1 (de) Verfahren zum Charakterisieren von biologischen Bedingungen, die kalibrierte Genexpressionsprofile verwenden
DE69938867D1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
DE60327199D1 (de) Verfahren zum screening auf agonistische antikörper
ATE351902T1 (de) Oberflächentransfektion und expressionsverfahren
ATE217905T1 (de) Zellinien, die einen biologisch aktiven faktor-ix exprimieren
IS2889B (is) Bv8 kjarnsýrur og fjölpeptíð með mítósu-valdandi verkun
WO2002101039A1 (en) Method of testing drug for treating or preventing diseases such as hyperlipemia
CY1108849T1 (el) Πολλαπλασιαμος του ιου κορωνα των βοοειδων σε κυτταρα ωοθηκων κινεζικων κρικητων
SE0002189D0 (sv) New method and assay
WO2003094841A3 (en) Mammalian genes involed in rapamycin resistance and tumorgenesis: annexin xiii genes
DE60128802D1 (de) Verfahren zum nachweis von genen von sekretierten proteinen
ATE403739T1 (de) Verfahren zur verwendung teilungsarretierter zellen in screening-assays
ATE501278T1 (de) Verfahren zur verwendung von il-21
Sohail Gene silencing by RNA interference: technology and application
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
AU2003241174A1 (en) Method of identifying pancreatic ductal carcinoma-specific gene using pancreatic ductal cells, method of testing for pdc using said genes, and method of screening pharmaceutical candidate compounds for treating or preventing pdc
Kaiser et al. Expanding horizons at Big Sky: Symposium on Ubiquitin and Signaling
AU2005291445A1 (en) Improved electrophoretic separation method for analyzing gene expression
DE60234097D1 (de) Chimere proteine zum targeting von zellen und der induktion von apoptose, und verfahren zu deren verwendung
Mavrantoni et al. Voltage Dependent Phosphatase Activity is Enhanced by Intracellular Acidification
ATE264387T1 (de) Verfahren zur auslösung von apoptose in zellen
ATE469175T1 (de) Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application